Radium Ra 223 dichloride in castration-resistant prostate cancer

Drugs of Today

Volumn 49, Issue 8, 2013, Pages 483-490

  Joung, J Y ^a,b   Ha, Y S ^a,c   Kim, I Y ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b National Cancer Center   (South Korea)

^c Chungbuk National University College of Medicine   (South Korea)

Author keywords

Bone metastasis; Castration resistant prostate cancer; Radionuclide therapy; Radium ra 223 dichloride

Indexed keywords

PLACEBO; RADIUM CHLORIDE RA 223; UNCLASSIFIED DRUG; XOFIGO;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; HEMATOLOGIC DISEASE; HUMAN; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL;

BONE METASTASIS; CASTRATION-RESISTANT PROSTATE CANCER; RADIONUCLIDE THERAPY; RADIUM RA 223 DICHLORIDE;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIUM; SURVIVAL RATE;

EID: 84883186993     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.8.1968670     Document Type: Article

References (56)

1. Siegel, R., naishadham, D., Jemal, A. Cancer statistics, 2012. Ca Cancer J Clin 2012. 62(1): 10-29.
2. Eisenberger, M.A., Blumenstein, B.A., Crawford, E.D. et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. n Engl J Med 1998. 339(15): 1036-42.
3. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000. 355(9214): 1491-8.
4. Sonpavde, G., Fleming, M.T., hutson, T.E., galsky, M.D. Trial design for metastatic castration-resistant prostate cancer. J Clin oncol 2008. 26(21): 3647-8.
5. petrylak, D.P., Tangen, C.M., hussain, M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. n Engl J Med 2004. 351(15): 1513-20.
6. Tannock, I.F., de Wit, R., Berry, W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. n Engl J Med 2004. 351(15): 1502-12.
7. Coleman, R.E. Skeletal complications of malignancy. Cancer 1997. 80(8, Suppl.): 1588-94.
8. Saad, F., gleason, D.M., Murray, R. et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J natl Cancer Inst 2004. 96(11): 879-82.
9. Kantoff, P.W., higano, C.S., Shore, N.D. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. n Engl J Med 2010. 363(5): 411-22.
10. de Bono, J.S., oudard, S., ozguroglu, M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010. 376(9747): 1147-54.
11. de Bono, J.S., Logothetis, C.J., Molina, A. et al. Abiraterone and increased survival in metastatic prostate cancer. n Engl J Med 2011. 364(21): 1995-2005.
12. Dumas, L., payne, H., Chowdhury, S. The evolution of antiandrogens: MDV3100 comes of age. Expert rev anticancer Ther 2012. 12(2): 131-3.
13. Mukherji, D., Eichholz, A., De Bono, J.S. Management of metastatic castration-resistant prostate cancer: recent advances. Drugs 2012. 72(8): 1011-28.
14. ratanatharathorn, V., powers, W.E., Moss, W.T., perez, C.A. Bone metastasis: review and critical analysis of random allocation trials of local field treatment. Int J radiat oncol Biol phys 1999. 44(1): 1-18.
15. Saarto, T., Janes, R., Tenhunen, M., Kouri, M. Palliative radiotherapy in the treatment of skeletal metastases. Eur J pain 2002. 6(5): 323-30.
16. Salazar, O.M., Sandhu, T., da Motta, N.W. et al. Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomraDIUM ized Phase III trial of the International Atomic Energy Agency (IAEA). Int J radiat oncol Biol phys 2001. 50(3): 765-75.
17. Kyrgidis, A., Tzellos, T.G. Denosumab in castration-resistant prostate cancer. Lancet 2012. 379(9828): e50.
18. Saad, F., gleason, D.M., Murray, R. et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J natl Cancer Inst 2002. 94(19): 1458-68.
19. Fizazi, K., Carducci, M., Smith, M. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, doubleblind study. Lancet 2011. 377(9768): 813-22.
20. Maxon, H.R., 3rd, Schroder, L.E., hertzberg, V.S. et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J nucl Med 1991. 32(10): 1877-81.
21. robinson, R.G., preston, D.F., Schiefelbein, M., Baxter, K.G. Strontium 8. Therapy for the palliation of pain due to osseous metastases. JaMa 1995. 274(5): 420-4.
22. Serafini, A.N., houston, S.J., resche, I. et al. Palliation of pain associated with metastatic bone cancer using samarium-15. lexidronam: a double-blind placebo-controlled clinical trial. J Clin oncol 1998. 16(4): 1574-81.
23. Breen, S.L., Battista, J.J. Cavity theory applied to the dosimetry of systemic radiotherapy of bone metastases. phys Med Biol 2000. 45(4): 879-96.
24. adam, A., Dixon, A., allison, D.J., grainger, R.G. grainger and allison's Diagnostic radiology: a Textbook of Medical Imaging. 5th Ed. Churchill Livingstone: Edinburgh 2008.
25. Lewington, V.J., McEwan, A.J., ackery, D.M. et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991. 27(8): 954-8.
26. Buchali, K., Correns, H.J., Schuerer, M., Schnorr, D., Lips, H., Sydow, K. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J nucl Med 1988. 14(7-8): 349-51.
27. porter, A.T., McEwan, A.J., powe, J.E. et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-8. adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J radiat oncol Biol phys 1993. 25(5): 805-13.
28. Quilty, P.M., Kirk, D., Bolger, J.J. et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. radiother oncol 1994. 31(1): 33-40.
29. oosterhof, G.O., roberts, J.T., de reijke, T.M. et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003. 44(5): 519-26.
30. Sartor, O., reid, R.H., hoskin, P.J. et al. Samarium-153- Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004. 63(5): 940-5.
31. Silberstein, E.B. Dosage and response in radiopharmaceutical therapy of painful osseous metastases. J nucl Med 1996. 37(2): 249-52.
32. Bouchet, L.G., Bolch, W.E., goddu, S.M., howell, R.W., rao, D.V. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J nucl Med 2000. 41(4): 682-7.
33. Krishnamurthy, G.T., Krishnamurthy, S. Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium. J nucl Med 2000. 41(4): 688. 91.
34. hosain, F., Spencer, R.P. Radiopharmaceuticals for palliation of metastatic osseous lesions: biologic and physical background. Semin nucl Med 1992. 22(1): 11-6.
35. Blake, G.M., gray, J.M., Zivanovic, M.A., McEwan, A.J., Fleming, J.S., ackery, D.M. Strontium-89 radionuclide therapy: a dosimetric study using impulse response function analysis. Br J radiol 1987. 60(715): 685-92.
36. Breen, S.L., powe, J.E., porter, A.T. Dose estimation in strontium-8. radiotherapy of metastatic prostatic carcinoma. J nucl Med 1992. 33(7): 1316-23.
37. hall, E.J., giaccia, A.J. radiology for radiologist. 5 Ed. J.B. Lippincott Williams & Wilkins: philadelphia 2000.
38. ritter, M.A., Cleaver, J.E., Tobias, C.A. High-LET radiations induce a large proportion of non-rejoining DNA breaks. nature 1977. 266(5603): 653-5.
39. Bruland, O.S., nilsson, S., Fisher, D.R., Larsen, R.H. Highlinear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer res 2006. 12(20, pt. 2): 6250s-7s.
40. hall, E.J., giaccia, A.J. radiobiology for the radiologist. 6 Ed. Lippincott Williams & Wilkins: philadelphia 2006.
41. Mazeron, J.J., gerbaulet, A. The centenary of discovery of radium. radiother oncol 1998. 49(3): 205-16.
42. nilsson, S., Larsen, R.H., Fossa, S.D. et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer res 2005. 11(12): 4451-9.
43. Tiepolt, C., gruning, T., Franke, W.G. Renaissance of 22. Ra for the treatment of ankylosing spondylitis: clinical experiences. nucl Med Commun 2002. 23(1): 61-6.
44. parker, C., heinrich, D., o'Sullivan, J.M. et al.Overall survival benefit and safety profile of radium-223 chloride, a first-inclass alpha- pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin oncol [genitourin Cancers Symp (Feb 2-4, San Francisco) 2012. 2012, 30(Suppl. 5): abst 8.
45. Dornish, M., heier-Baardson, H., pettersen, E.O. Cellular effects of alpha particle radiation from radium-223: ALPHARADIN, a new radiopharmaceutical for the treatment of skeletal metastases. proc am assoc Cancer res (aaCr) 2008. 49: abst 5749.
46. Larsen, R.H., Murud, K.M., akabani, G., hoff, P., Bruland, O.S., Zalutsky, M.R. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. J nucl Med 1999. 40(7): 1197-203.
47. [genitourin Cancers Symp (Feb 2-4, San Francisco)2012]
48. henriksen, G., Fisher, D.R., roeske, J.C., Bruland, O.S., Larsen, R.H. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J nucl Med 2003. 44(2): 252-9.
49. henriksen, G., Breistol, K., Bruland, O.S., Fodstad, O., Larsen, R.H. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer res 2002. 62(11): 3120-5.
50. hindorf, C., Flux, G., Lewington, V. aksnes, A.K., harris, P., parker, C. A biodistribution and dosimetry study of therapeutic 223Ra-chloride (Alpharadin) in patients with osteoblastic skeletal metastases secondary to hormone refractory prostate cancer. J nucl Med 2008. 49(Suppl. 1): 145p.
51. Carrasquillo, J.A., Donoghue, J.A., pandit-Taskar, N. et al. Phase I pharmacokinetic (PK) and biodistribution study of radium-223 chloride in patients with castration resistant prostate cancer (CRPC) metastatic to bone. 46th annu Meet am Soc Clin oncol (aSCo) (June 4-8, Chicago) 2010. abst 4680.
52. Smeland, S., Erikstein, B., aas, M., Skovlund, E., hess, S.L., Fossa, S.D. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: Results of a double-blind randomized study. Int J radiat oncol Biol phys 2003. 56(5): 1397-404.
53. nilsson, S., Balteskard, L., Fossa, S.D. et al. Phase I study of Alpharadin2 (223Ra), and a-emitting bone-seeking agent in cancer patients with skeletal metastases. Eur J nucl Med Mol Imaging 2004. 31(S2): S290.
54. nilsson, S., Franzen, L., parker, C. et al. Bone-targeted radium-22. in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet oncol 2007. 8(7): 587-94.
55. nilsson, S., Strang, P., aksnes, A.K. et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012. 48(5): 678-86.
56. Sartor, A.O., heinrich, D., helle, S.I. et al Radium-223 chloride impact on skeletal-related events in patients with castration- resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA). J Clin oncol [genitourin Cancers Symp (Feb 2-4, San Francisco) 2012. 2012, 30(Suppl. 5): abst 9.